Table 1.
Proposed regimens for MDR-TB preventive therapy*.
| Drug/regimen** | Dose and duration of treatment |
|---|---|
|
Single drug regimen
|
|
| FQN alone |
Lfx: 15–20 mg/kg/day (max 750 mg) OR Mfx: 10–15 mg/kg/day (max 400 mg) Duration: 6–12 months# |
|
Two-drug regimen
|
|
| FQN and EMB |
FQN as above + EMB: 15–25 mg/kg/day (max
1 g) Duration: 6–12 months# |
| FQN and ETH |
FQN as above + ETH: 15–20 mg/kg/day (max
1 g) Duration: 6–12 months# |
| FQN and high dose INH |
FQN as above + INH: 15–20 mg/kg/day (max
450 mg) Duration: 6–12 months# |
|
Three-drug regimen
|
|
| FQN and ETH and high dose INH | FQN as above + ETH as above + INH as aboveDuration: 6–12 months#
|
EMB, ethambutol; ETH, ethionamide; FQN, fluoroquinolone; INH, isoniazid; MDR, multidrug-resistant (resistance to isoniazid and rifampicin); Mfx, moxifloxacin; Lfx, levofloxacin.
*
Currently no guidance exists for MDR-TB infection with FQN resistance; high dose INH could be considered if the source case has a inhA mutation or low level INH resistance; trials using delamanid are being planned; **Choice of regimen based on drug susceptibility testing of likely source case.